Nicole Defeudis is an Editor at Endpoints News. She specializes in biopharma reporting, with a focus on medicine and healthcare, including topics such as the FDA, Coronavirus, and legal affairs related to health and wellness. Nicole's work has been featured in Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Nicole's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly around regulatory approvals, legal policy regulation, and government announcements. She appears to be interested in stories related to FDA approvals, drug pricing, mergers and acquisitions within the pharmaceutical space.
To effectively reach out to Nicole with a pitch or as a source for her articles, it would be beneficial to provide insights or expertise related to recent developments in FDA regulations and approvals, legal challenges faced by pharmaceutical companies such as patent disputes or antitrust issues. Additionally, commentary on the implications of regulatory changes on drug pricing could also resonate well with her coverage focus.
It is important to note that Nicole tends to cover topics without geographic constraints explicitly mentioned. Therefore, pitches should focus on providing broader industry-specific insights rather than region-specific news unless otherwise indicated.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Nicole DeFeudis
Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle with a slow RSV launch and …
Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report. The company's estimates have varied …
By: Nicole DeFeudis, Gene Tx
The Department of Health and Human Services says Vertex is “grasping at straws” in a lawsuit challenging the agency's decision to reject its proposed fertility …
By: Nicole DeFeudis
HHS told the Second Circuit that Boehringer Ingelheim's voluntary participation in Medicare negotiations “undermines” its legal challenge to the process.
By: Nicole DeFeudis
Teva is the latest drugmaker to file suit against Medicare negotiations. But unlike other companies that have challenged the inclusion of their drugs in negotiations …
By: Nicole DeFeudis
Novo Nordisk's blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government's Medicare negotiation program under the Inflation Reduction …
By: Max Gelman, Nicole DeFeudis
Welcome back to the new and improved Endpoints Weekly! This week we'll be recapping the JP Morgan Healthcare Conference, IRA price negotiations, Pfizer's plans to …
By: Nicole Defeudis
Meena Seshamani believes the landmark Inflation Reduction Act will “lay the foundation” for future drug price negotiations under the incoming Trump administration. The former Medicare director says drugmakers may still see some change to how it plays out.
The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health information that’s vital for pharmaceutical companies, academics said Tuesday.
By: Nicole DeFeudis
AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But this time around, the company says …
(833) 317-6278 
